Shandong Runxin

Shandong Runxin Biotechnology is a clinical-stage biopharmaceutical company headquartered in Jinan, China, with a focus on developing innovative small molecule therapeutics for oncology. The company's lead candidate, RX-208, is a highly selective BRAF V600E inhibitor currently undergoing pivotal clinical trials for colorectal cancer and other BRAF-mutant solid tumors in collaboration with Betta Pharmaceuticals. Another significant program, RX-108, is a first-in-class inhibitor of Na+/K+-ATPase being evaluated for the treatment of glioblastoma and other advanced cancers. Runxin's pipeline also includes RX-0047, a fibroblast growth factor receptor (FGFR) inhibitor, and several earlier-stage discovery programs. Founded by industry veterans, the company leverages its R&D centers in Jinan and Suzhou to advance a portfolio of targeted therapies aimed at addressing significant unmet needs in the global oncology landscape.